mRNA as novel technology for passive immunotherapy

por Schlake, Thomas, Thess, Andreas, Thran, Moritz, Jordan, Ingo
Publicado 2018

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals

por Thess, Andreas, Grund, Stefanie, Mui, Barbara L, Hope, Michael J, Baumhof, Patrick, Fotin-Mleczek, Mariola, Schlake, Thomas
Publicado 2015

A novel, disruptive vaccination technology: Self-adjuvanted RNActive(®) vaccines

por Kallen, Karl-Josef, Heidenreich, Regina, Schnee, Margit, Petsch, Benjamin, Schlake, Thomas, Thess, Andreas, Baumhof, Patrick, Scheel, Birgit, Koch, Sven D, Fotin-Mleczek, Mariola
Publicado 2013

mRNA mediates passive vaccination against infectious agents, toxins, and tumors

por Thran, Moritz, Mukherjee, Jean, Pönisch, Marion, Fiedler, Katja, Thess, Andreas, Mui, Barbara L, Hope, Michael J, Tam, Ying K, Horscroft, Nigel, Heidenreich, Regina, Fotin‐Mleczek, Mariola, Shoemaker, Charles B, Schlake, Thomas
Publicado 2017

mRNA as a Novel Treatment Strategy for Hereditary Spastic Paraplegia Type 5

por Hauser, Stefan, Poenisch, Marion, Schelling, Yvonne, Höflinger, Philip, Schuster, Stefanie, Teegler, Axel, Betten, Rabea, Gustafsson, Jan-Åke, Hübener-Schmid, Jeannette, Schlake, Thomas, Chevessier-Tünnesen, Frédéric, Horscroft, Nigel, Björkhem, Ingemar, Schöls, Ludger
Publicado 2019